As someone who follows the food services and facilities management space closely, I see ARMK as a steady player navigating a competitive environment driven by demand from education, healthcare, and business sectors. This upcoming Q2 fiscal 2026 earnings report, set for today, May 12, 2026, feels particularly important. It comes on the heels of a strong Q1, where revenue reached $4.83 billion, up 6% year-over-year, even with a headwind from the fiscal 2025 53rd week calendar shift. From what I see, investors will be looking for signs of continued organic growth, new business wins, and steady progress toward full-year goals, especially as inflation moderates and business & industry (B&I) volumes recover. Solid results here could further validate the company's multi-year turnaround efforts.
Wall Street's projections point to consolidated revenue of around $4.76 billion for Q2 fiscal 2026, which ended roughly in April 2026, marking about 11% growth from the $4.33 billion reported in the year-ago quarter. The consensus for adjusted EPS sits at $0.47 to $0.48, representing a 38%-41% jump from $0.34 last year, fueled by operational leverage and contributions from new business. Expectations break down to FSS United States revenue at $3.39 billion (up 10.9%) and FSS International at $1.39 billion (up 14%).
Q1 demonstrated real resilience: organic revenue grew 5% to a total of $4.8 billion, adjusted EPS held flat at $0.51 (which would have been up 13% without the shift), and adjusted operating income (AOI) rose 1%. Management has flagged a tailwind for Q2 from that prior 53rd week shift. The full-year guidance remains unchanged: revenue of $19.55-$19.95 billion (7%-9% organic growth), AOI growth of 12%-17%, adjusted EPS of $2.18-$2.28 (20%-25% growth), and leverage below 3.0x (net debt to AOI). I'll be paying close attention to net new business (targeting 4%-5%), client retention rates, and margins in the face of food and labor cost pressures.
One thing that stands out to me is the cautiously optimistic sentiment around ARMK heading into these results. Shares have held up well since the Q1 revenue and EPS beats, posting modest gains even amid broader market swings. Analysts highlight upside potential in B&I and education volumes, though risks like contract delays or inflation-driven margin squeezes remain on the radar. Historically, the stock has reacted positively to beats—for instance, up 2% after-hours following Q1—though reaffirmation of guidance will likely be the deciding factor. Options pricing suggests limited volatility is baked in.
I also checked this using Tickeron’s AI Screener to see how ARMK stacks up against peers on technical patterns, fundamentals, and trends. This AI-powered tool scans thousands of stocks and ETFs with customizable filters like industry, market cap, and performance metrics, helping pinpoint opportunities more efficiently than manual reviews. In my view, it's a practical way to enhance analysis without the guesswork—worth exploring if you're screening for similar names.
In my view, Aramark's reaffirmed FY2026 guidance signals real confidence, with organic revenue growth targeted at 7%-9% and adjusted EPS expanding 20%-25% to $2.18-$2.28. This outlook builds directly on Q1 momentum, including net new business wins in healthcare (such as RWJ Barnabas), education, corrections, sports, and mining, plus record retention above 95%.
I'm watching Q2 progress toward the 4%-5% net new business target closely, backed by a strong pipeline where over 40% comes from first-time outsourcing. The calendar shift tailwind should support FSS United States revenue growth, particularly in B&I and higher education.
Other elements to track include AI-driven efficiencies in the supply chain, group purchasing organization (GPO) spend surpassing $20 billion, and recent debt repricings that lower interest expenses. Keep an eye on cost trends—food and labor inflation is tracking plans—and progress toward leverage under 3.0x. With upcoming contract ramps and 17 straight quarters of double-digit international growth, these results will offer insight into demand resilience in an uncertain economy.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
ARMK's Aroon Indicator triggered a bullish signal on June 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 288 similar instances where the Aroon Indicator showed a similar pattern. In of the 288 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ARMK as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARMK advanced for three days, in of 321 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for ARMK moved out of overbought territory on June 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 68 cases where ARMK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ARMK turned negative on June 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARMK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.292) is normal, around the industry mean (15.631). P/E Ratio (39.963) is within average values for comparable stocks, (70.665). Projected Growth (PEG Ratio) (0.928) is also within normal values, averaging (1.465). Dividend Yield (0.009) settles around the average of (0.023) among similar stocks. P/S Ratio (0.735) is also within normal values, averaging (8.684).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARMK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a holding company with interests in food services and facilities management
Industry OfficeEquipmentSupplies